Advertisement

Molecular Medicine

, Volume 23, Issue 1, pp 295–306 | Cite as

RAGE-aptamer Attenuates the Growth and Liver Metastasis of Malignant Melanoma in Nude Mice

  • Nobutaka Nakamara
  • Takanori Matsui
  • Yuji Ishibashi
  • Ami Sotokawauchi
  • Kei Fukami
  • Yuichiro Higashimoto
  • Sho-ichi Yamagishi
Research Article

Abstract

Epidemiological studies have suggested a link between cumulative diabetic exposure and cancer. The interaction of advanced glycation end products (AGEs) with their receptor (RAGE) may contribute to the phenomenon. We examined the effects of DNA aptamer raised against RAGE (RAGE-aptamer) on growth and liver metastasis of G361 melanoma in nude mice. Malignant melanoma cells were intradermally injected into the upper flank region of nude mice, which received continuous administration of RAGE-aptamer (38.4 pmol/day/g body weight) or vehicle intraperitoneally by an osmotic pump up to 42 d. RAGE-aptamer significantly reduced levels of 8-hydroxy-2′-deoxy-guanosine, AGEs, RAGE, proliferating nuclear antigen, cyclin D1, vascular endothelial growth factor (VEGF), monocyte chemoattractant protein-1 (MCP-1), and CD31 and Mac-3, respective markers of endothelial cells and macrophages in tumors of nude mice, and suppressed proliferation and liver metastasis of malignant melanoma. Furthermore, RAGE-aptamer attenuated AGE-induced oxidative stress generation, proliferation, and VEGF and MCP-1 gene expression in both G361 melanoma cells and endothelial cells. The present findings suggest that RAGE-aptamer could attenuate melanoma growth and liver metastasis in nude mice by suppressing tumor angiogenesis and macrophage infiltration via inhibition of the AGE-RAGE system. RAGE-aptamer may be a novel therapeutic tool for the treatment of malignant melanoma.

Notes

Acknowledgments

This work was supported in part by Grants-in-Aid for Scientific Research C (grant number 16K07101) (T.M.) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan and by The Mitsubishi Foundation (ID 27147, S.Y.), Japan.

References

  1. 1.
    International Diabetes Federation. (2016) Diabetes Atlas, 7th ed. [Internet]. Available from https://doi.org/www.diabetesatlas.org. Accessed May 21, 2017.
  2. 2.
    Braithwaite D, Boffetta P, Rebbeck TR, Meyskens F. (2012) Cancer prevention for global health: a report from the ASPO International Cancer Prevention Interest Group. Cancer Epidemiol. Biomarkers Prev. 21:1606–10.CrossRefGoogle Scholar
  3. 3.
    Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R. (2009) Diabetes and cancer. Endocr. Relat. Cancer. 16:1103–23.CrossRefGoogle Scholar
  4. 4.
    Barone BB, et al. (2008) Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA. 300:2754–64.CrossRefGoogle Scholar
  5. 5.
    Stattin P, et al. (2007) Prospective study of hyperglycemia and cancer risk. Diabetes Care. 30:561–67.CrossRefGoogle Scholar
  6. 6.
    Emerging Risk Factors Collaboration, Seshasai SR, et al. (2011) Diabetes mellitus, fasting glucose, and risk of cause-specific death. N. Engl. J. Med. 364:829–41.CrossRefGoogle Scholar
  7. 7.
    Brownlee M, Cerami A, Vlassara H. (1988) Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N. Engl. J. Med. 318:1315–21.CrossRefGoogle Scholar
  8. 8.
    Dyer DG, Blackledge JA, Thorpe SR, Baynes JW. (1991) Formation of pentosidine during nonenzymatic browning of proteins by glucose. Identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo. J. Biol. Chem. 266:11654–60.PubMedGoogle Scholar
  9. 9.
    Genuth S, et al. (2005) Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes. Diabetes. 54:3103–11.CrossRefGoogle Scholar
  10. 10.
    Bucala R. (2014) Diabetes, aging, and their tissue complications. J. Clin. Invest. 124:1887–88.CrossRefGoogle Scholar
  11. 11.
    Yamagishi SI, Nakamura N, Matsui T. (2017) Glycation and cardiovascular disease in diabetes: A perspective on the concept of metabolic memory. J. Diabetes. 9:141–48.CrossRefGoogle Scholar
  12. 12.
    Fleming TH, Humpert PM, Nawroth PP, Bierhaus A. (2011) Reactive metabolites and AGE/RAGE-mediated cellular dysfunction affect the aging process: a mini-review. Gerontology. 57:435–43.PubMedGoogle Scholar
  13. 13.
    Ramasamy R, Yan SF, Schmidt AM. (2011) Receptor for AGE (RAGE): signaling mechanisms in the pathogenesis of diabetes and its complications. Ann. NY Acad. Sci. 1243:88–102.CrossRefGoogle Scholar
  14. 14.
    Ward MS, Fortheringham AK, Cooper ME, Forbes JM. (2013) Targeting advanced glycation endproducts and mitochondrial dysfunction in cardiovascular disease. Curr. Opin. Pharmacol. 13:654–61.CrossRefGoogle Scholar
  15. 15.
    Chen M, Curtis TM, Stitt AW. (2013) Advanced glycation end products and diabetic retinopathy. Curr. Med. Chem. 20:3234–40.CrossRefGoogle Scholar
  16. 16.
    Yamagishi S, Matsui T, Fukami K. (2015) Role of receptor for advanced glycation end products (RAGE) and its ligands in cancer risk. Rejuvenation Res. 18:48–56.CrossRefGoogle Scholar
  17. 17.
    Yamamoto Y, Yamagishi S, Hsu CC, Yamamoto H. (1996) Advanced glycation end products: receptor interactions stimulate the growth of human pancreatic cancer cells through the induction of platelet-derived growth factor-B. Biochem. Biophys. Res. Commun. 222:700–05.CrossRefGoogle Scholar
  18. 18.
    Abe R, et al. (2004) Regulation of human melanoma growth and metastasis by AGE-AGE receptor interactions. J. Invest. Dermatol. 122:461–67.CrossRefGoogle Scholar
  19. 19.
    Ishibashi Y, Matsui T, Takeuchi M, Yamagishi S. (2013) Metformin inhibits advanced glycation end products (AGEs)-induced growth and VEGF expression in MCF-7 breast cancer cells by suppressing AGEs receptor expression via AMP-activated protein kinase. Horm. Metab. Res. 45:387–390.PubMedGoogle Scholar
  20. 20.
    Ellington AD, Szostak JW. (1990) In vitro selection of RNA molecules that bind specific ligands. Nature. 346:818–22.CrossRefGoogle Scholar
  21. 21.
    Sun H, Zu Y. (2015) A highlight of recent advances in aptamer technology and its application. Molecules. 20:11959–80.CrossRefGoogle Scholar
  22. 22.
    Matsui T, et al. (2017) RAGE-aptamer blocks the development and progression of experimental diabetic nephropathy. Diabetes. 66:1683–95.CrossRefGoogle Scholar
  23. 23.
    Yamagishi S, et al. (2006) Pigment epithelium-derived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression. J. Biol. Chem. 281:20213–20.CrossRefGoogle Scholar
  24. 24.
    Ojima A, et al. (2014) DNA aptamer raised against advanced glycation end products inhibits melanoma growth in nude mice. Lab. Invest. 94:422–29.CrossRefGoogle Scholar
  25. 25.
    Matsui T, Nishino Y, Takeuchi M, Yamagishi S. (2011) Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product-receptor axis. Pharmacol. Res. 63:383–88.CrossRefGoogle Scholar
  26. 26.
    Matsui T, Oda E, Higashimoto Y, Yamagishi S. (2015) Glyceraldehyde-derived pyridinium (GLAP) evokes oxidative stress and inflammatory and thrombogenic reactions in endothelial cells via the interaction with RAGE. Cardiovasc. Diabetol. 14:1.CrossRefGoogle Scholar
  27. 27.
    Ishibashi Y, Matsui T, Yamagishi S. (2016) Tofogliflozin, a highly selective inhibitor of SGLT2, blocks proinflammatory and proapoptotic effects of glucose overload on proximal tubular cells partly by suppressing oxidative stress generation. Horm. Metab. Res. 48:191–95.PubMedGoogle Scholar
  28. 28.
    Higashimoto Y, et al. (2007) In vitro selection of DNA aptamers that block toxic effects of AGE on cultured retinal pericytes. Microvasc. Res. 74:65–69.CrossRefGoogle Scholar
  29. 29.
    Ishibashi Y, Matsui T, Ueda S, Fukami K, Yamagishi S. (2014) Advanced glycation end products potentiate citrated plasma-evoked oxidative and inflammatory reactions in endothelial cells by up-regulating protease-activated receptor-1 expression. Cardiovasc. Diabetol. 13:60.CrossRefGoogle Scholar
  30. 30.
    Nakamura K, et al. (2007) Pigment epithelium-derived factor inhibits neointimal hyperplasia after vascular injury by blocking NADPH oxidase-mediated reactive oxygen species generation. Am. J. Pathol. 170:2159–70.CrossRefGoogle Scholar
  31. 31.
    Cassarino DS, Cabral ES, Kartha RV, Swetter SM. (2008) Primary dermal melanoma: distinct immunohistochemical findings and clinical outcome compared with nodular and metastatic melanoma. Arch. Dermatol. 144:49–56.CrossRefGoogle Scholar
  32. 32.
    Gammon B, Ali L, Guitart J, Gerami P. (2012) Homogeneous staining regions for cyclin D1, a marker of poor prognosis in malignant melanoma. Am. J. Dermatopathol. 34:487–90.CrossRefGoogle Scholar
  33. 33.
    Abe R, Yamagishi S. (2008) AGE-RAGE system and carcinogenesis. Curr. Pharm. Des. 14:940–55.CrossRefGoogle Scholar
  34. 34.
    Yamagishi S, et al. (2004) Minodronate, a newly developed nitrogen-containing bisphosphonate, suppresses melanoma growth and improves survival in nude mice by blocking vascular endothelial growth factor signaling. Am. J. Pathol. 165:1865–74.CrossRefGoogle Scholar
  35. 35.
    Senger DR, et al. (1993) Vascular permeability factor in tumor biology. Cancer Metastasis Rev. 12:303–24.CrossRefGoogle Scholar
  36. 36.
    Torisu H, et al. (2000) Macrophage infiltration correlates with tumor stage and angiogenesis in human malignant melanoma: possible involvement of TNFalpha and IL-1alpha. Int. J. Cancer. 85:182–88.CrossRefGoogle Scholar
  37. 37.
    Salven P, Heikkila P, Joensuu H. (1997) Enhanced expression of vascular endothelial growth factor in metastatic melanoma. Br. J. Cancer. 76:930–34.CrossRefGoogle Scholar
  38. 38.
    Koga M, et al. (2008) Mutant MCP-1 therapy inhibits tumor angiogenesis and growth of malignant melanoma in mice. Biochem. Biophys. Res. Commun. 365:279–84.CrossRefGoogle Scholar
  39. 39.
    Shi L, et al. (2010) Clinicopathological implications of tumour-associated macrophages and vascularization in sinonasal melanoma. J. Int. Med. Res. 38:1276–86.CrossRefGoogle Scholar
  40. 40.
    Chen P, et al. (2011) Tumor-associated macrophages promote angiogenesis and melanoma growth via adrenomedullin in a paracrine and autocrine manner. Clin. Cancer Res. 17:7230–39.CrossRefGoogle Scholar
  41. 41.
    Yamagishi S, et al. (1997) Advanced glycation end products-driven angiogenesis in vitro. Induction of the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor. J. Biol. Chem. 272:8723–30.CrossRefGoogle Scholar
  42. 42.
    Matsui T, Nakamura N, Ojima A, Nishino Y, Yamagishi SI. (2016) Sulforaphane reduces advanced glycation end products (AGEs)-induced inflammation in endothelial cells and rat aorta. Nutr. Metab. Cardiovasc. Dis. 26:797–807.CrossRefGoogle Scholar
  43. 43.
    Chang JS, et al. (2008) Oxygen deprivation triggers upregulation of early growth response-1 by the receptor for advanced glycation end products. Circ. Res. 102:905–13.CrossRefGoogle Scholar
  44. 44.
    Kaida Y, et al. (2013) DNA aptamer raised against AGEs blocks the progression of experimental diabetic nephropathy. Diabetes. 62:3241–50.CrossRefGoogle Scholar
  45. 45.
    Soro-Paavonen A, et al. (2008) Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes. 57:2461–69.CrossRefGoogle Scholar
  46. 46.
    Yang H, Wang H, Chavan SS, Andersson U. (2015) High Mobility Group Box Protein 1 (HMGB1): The Prototypical Endogenous Danger Molecule. Mol. Med. 21(Suppl 1):S6–12.CrossRefGoogle Scholar

Copyright information

© The Author(s) 2017

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license. You do not have permission under this license to share adapted material derived from this article or parts of it.

The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this license, visit (https://doi.org/creativecommons.org/licenses/by-nc-nd/4.0/)

Authors and Affiliations

  • Nobutaka Nakamara
    • 1
  • Takanori Matsui
    • 1
  • Yuji Ishibashi
    • 1
  • Ami Sotokawauchi
    • 1
  • Kei Fukami
    • 2
  • Yuichiro Higashimoto
    • 3
  • Sho-ichi Yamagishi
    • 1
  1. 1.Department of Pathophysiology and Therapeutics of Diabetic Vascular ComplicationsKurume University School of MedicineKurumeJapan
  2. 2.Department of MedicineKurume University School of MedicineKurumeJapan
  3. 3.Department of ChemistryKurume University School of MedicineKurumeJapan

Personalised recommendations